SEO URLwww.firestrike.ai/deals/adverum-biotechnologies-lilly-acquisition-2026
acquisitionAnnounced · Jan 3, 2026BiotechnologySource · CredibleArticle · Factual
Lilly acquires Adverum Biotechnologies
David Najork · Founding Software Engineer
Published · Updated · 1 min read
Deal value
—
Target
Adverum Biotechnologies
NASDAQ: ADVM · Redwood City, California
Acquirer
Lilly
Full Acquisition
Status
Pending
Lilly agreed to acquire Adverum Biotechnologies. Reported deal value: Undisclosed. Status: Pending. Sector: Biotechnology. Target headquarters context: Redwood City, California, United States.
This page summarizes publicly available information about the transaction as of 2026-01-03. Figures and status may change as filings and press coverage update.
The Eli Lilly and Company will acquire Adverum Biotechnologies , according to a joint press release issued by the 2 companies
Deal timeline
Announced
Jan 3, 2026 · ophthalmologytimes.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Biotechnology. Figures and status may change as sources update.
Sources: ophthalmologytimes.com · Primary article · FireStrike proprietary index